Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2018) Heikki Joensuu et al.   JAMA Oncology

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

(2018) P Conte et al.   ANNALS OF ONCOLOGY

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

(2017) Saro H. Armenian et al.   JOURNAL OF CLINICAL ONCOLOGY

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

(2017) David Cameron et al.   LANCET

SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left Ventricular Function

(2017) Filipa Lynce et al.   ONCOLOGIST

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter

(2016) Chau T. Dang et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

(2016) Pooja P. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium

(2016) Shanly C. Seferina et al.   ONCOLOGIST

Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

(2015) Anthony F. Yu et al.   BREAST CANCER RESEARCH AND TREATMENT

Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction

(2015) A. F. Yu et al.   ONCOLOGIST

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2014) Juan Carlos Plana et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

(2011) Gunter von Minckwitz et al.   EUROPEAN JOURNAL OF CANCER

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

HFSA 2010 Comprehensive Heart Failure Practice Guideline

(2010) Heart Failure Society of America   JOURNAL OF CARDIAC FAILURE